

## **AGENDA FOR THE 91st MEETING OF EAGA**

**Wednesday 22 February 2012 at 10.30 am**

- |     |   |                 |
|-----|---|-----------------|
| 1.  | <b>Welcome, introductions, apologies and announcements</b>  | 10.30-10.40     |
| 2.  | <b>Minutes of the previous meeting – 19 October 2011 (EAGA 90)</b>  | 10.40-10.45     |
| 3.  | <b>Matters arising:</b>   | 10.45-11.00     |
| 3.1 | Report from the Secretariat <b>Paper EAGA(91)1</b>  | For information |
| 3.2 | Correspondence between the Chief Executive of the National Policing Improvement Agency and the EAGA and AGH Chairs <b>Paper EAGA(91)2</b> |                 |

### **Agenda items**

- |     |   |             |
|-----|---|-------------|
| 4.  | <b>Reconstructing the MSM epidemic in the UK: model of HIV transmission, progression and the effect of ART</b>  | 11.00-11.30 |
| 5.  | <b>Impact of the health reforms on HIV prevention, treatment and care (SP 1&amp;2)</b>  | 11.30-12.00 |
| 6.  | <b>EAGA position statement on “HIV transmission within serodiscordant partnerships where the positive partner is on successful antiretroviral therapy”: draft for discussion</b> <b>Paper EAGA(91)3</b> | 12.00-12.30 |
| 7.  | <b>Management of HIV-infected healthcare workers</b> <b>Paper EAGA(91)4</b>   | 12.30-13.00 |
| 7.1 | Feedback from EAGA on consultation questions (SP3)  |             |
| 7.2 | Risk of viral rebound from below 50 copies/ml (SP4&5)   |             |
| 7.3 | HIV elite control – implications for HIV-infected healthcare workers  |             |

<b>LUNCH</b>	13.00-13.30
--------------	-------------

- |     |  |             |
|-----|--|-------------|
| 8.  | <b>HIV testing and follow-up into care</b>   | 13.30-13.50 |
| 8.1 | Access to and retention in HIV care - national data on loss to follow-up (SP6)   |             |
| 8.2 | Audit of HIV patients lost to follow-up  |             |
| 9.  | <b>Update on PrEP initiatives</b> <b>Paper EAGA(91)5</b>   | 13.50-14.05 |
| 10. | <b>Briefing on standards for management of HIV-infected prisoners and immigration detainees</b> <b>Paper EAGA(91)6</b>   | 14.05-14.15 |
| 11. | <b>Update from DH covering testing kit regulations, guidance for Local Authorities on sharing information on STIs, charging regulations, tender for a national HIV prevention programme and sexual health policy framework</b> | 14.15-14.30 |

12. **Any other business** 14.30-15.00

12.1 HIV PEP guidance: do we need an addendum? **Paper EAGA(91)7**

12.2 WHO guidance on and hormonal contraception and HIV infection

12.3 Review of 2011/12 workplan and planning for 2012/13  
**Paper EAGA(91)8**

13. **Dates of the next meetings: 13 June 2012, 17 October 2012** 15.00 close

.....

### **Supporting papers**

#### **For agenda item 5**

1. a [The new Public Health System](#): summary  
b. [Public Health in Local Government](#): factsheets
2. a Improving outcomes and supporting transparency. [Part 1: A public health outcomes framework for England, 2013-2016](#).  
b. Improving outcomes and supporting transparency. [Part 2: Summary technical specifications of public health indicators, January 2012](#).

#### **For agenda item 7.1**

3. Department of Health. [Management of HIV-infected healthcare workers: a paper for consultation](#). 1 December 2011.
4. Doyle T et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54:729-737.  
<http://cid.oxfordjournals.org/content/early/2012/01/09/cid.cir936.full.pdf+html>
5. Gandhi RJ and Deeks SG. Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?  
<http://cid.oxfordjournals.org/content/early/2012/01/09/cid.cir933.full.pdf+html>

#### **For agenda item 8**

6. Rice BD et al. Loss to follow-up among adults attending Human Immunodeficiency Virus services in England, Wales and Northern Ireland. Sex Transm Dis 2011; 38:685-90.

### **Information papers**

1. Health Protection Agency. [HIV in the United Kingdom: 2011 Report](#). London: Health Protection Services, Colindale. November 2011.

2. Health Protection Agency. [Sexually transmitted infections in men who have sex with men in the UK: 2011 Report](#). London: Health Protection Services, Colindale. November 2011.
3. Benn P et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS 2011; 22:695-708. Available from: <http://www.bashh.org/guidelines>
4. National Institute for Health and Clinical Excellence. [Clinical Guideline 132: Caesarean section](#). November 2011.
5. Hughes JP et al. [Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples](#). JID 2012; 205:358-65.
6. Ambrosioni J, Calmy A and Hirschel B. [HIV treatment for prevention](#). J Int AIDS Soc 2011; 14:28. Doi:10.1186/1758-2652-14-28
7. [WHO to issue guidance on hormonal contraceptives and HIV](#). Press release 3 February 2012.
8. Hogan CM et al. [The setpoint study \(ACTG A5217\): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals](#). JID 2012; 205:87-96.
9. Delaugerre C et al. [HIV-1 group N: travelling beyond Cameroon](#). Lancet 2011; 378:1894.
10. [Latest UK HIV data reinforce the need for “universal HIV testing” in high prevalence areas](#). Health Protect Rep 2011; 5(48).
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. [Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents](#). Department of Health and Human Services. October 14, 2011; 1–167.
12. European AIDS Clinical Society. [Guidelines \(version 6.0\)](#). October 2011.

## **PrEP**

13. Sigma Research. [The Sigma Panel Insight Blast 6: Prospective attitudes to HIV pre-exposure prophylaxis \(PrEP\)](#). London. October 2011.
14. [NIH modifies ‘VOICE’ HIV prevention study in women: oral tenofovir discontinued in clinical trial](#). 28 September 2011.
15. [Microbicide trials network statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women](#). 25 November 2011.
16. Patterson KB et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3, 112re4.